PCVII COST EFFECTIVENESS OF ADDING NIASPANTO ATORVASTATIN TREATMENT IN THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN PATIENTS WITH DYSLIPIDEMIA IN THE UK
Nov 1, 2004, 00:00 AM
10.1016/S1098-3015(10)65793-2
https://www.valueinhealthjournal.com/article/S1098-3015(10)65793-2/fulltext
Section Title :
Section Order :
160
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65793-2&doi=10.1016/S1098-3015(10)65793-2